Results 181 to 190 of about 53,142 (237)

Yixin Tongbi formula as a therapeutic approach for atherosclerosis by targeting inflammatory mediators and metalloproteinases. [PDF]

Sci Rep
Nie Q, Sattar H, Leng T, Wang R, Huang A, Wen X.   +5 more
europepmc   +1 more source

Evaluation of the anti-inflammatory potential of atorvastatin targeting TNF-α, IL-6, and IL-1β using integrated in vitro and in silico approaches. [PDF]

Sci Rep
Swaroop K, M R, Shaik S, Thatipelli RC, Krishna KVS, Ali Sangi SM, Islam MM, Meravanige G, Sreeharsha N, Chohan MS, Thapa S, Akin-Adewumi A, Atoki AV.   +12 more
europepmc   +1 more source

Functional and Patient-Reported Outcomes in the Atorvastatin versus Placebo Trial of Hemorrhagic Cerebral Cavernous Malformations: An Exploratory Study.

Cerebrovasc Dis
Sader G, Alcazar-Felix RJ, Jhaveri A, Ali B, Stadnik A, Lee J, Shenkar R, Treine K, McBee N, Girard R, Thompson RE, Hanley DF, Awad I, Flemming KD.   +13 more
europepmc   +1 more source

A peripheral blood-based approach involving vimentin along with AURKA enabled efficient tracking of elusive Oct4/Sox2-expressing disseminated breast cancer stem cells. [PDF]

Biosci Rep
Sengupta D, Thakur D, Mahapatra E, Das S, Chakrabarti J, Sen S, Mukherjee S.   +6 more
europepmc   +1 more source

Diagnostic and Therapeutic Challenges in Statin-Induced Necrotizing Autoimmune Myopathy in an Elderly Patient: A Rare Case Report. [PDF]

Clin Case Rep
Shrestha N, Hassan A, Evans JA.
europepmc   +1 more source

Synergistic effects of arsenic trioxide and atorvastatin on proliferation and apoptosis in acute lymphoblastic leukemia cells. [PDF]

Leuk Res Rep
Hassanpour Khodaei S, Sabetkam S, Mazloumi Z, Rafat A, Hekari D, Dizaji Asl K.   +5 more
europepmc   +1 more source

Data Mining of the Japanese Adverse Drug Event Report Database and Animal Experiments for Assessment of Risks Associated With Pemafibrate. [PDF]

In Vivo
Kobuchi S, Nishida M, Hayakawa M, Maekawa Y, Ohata A, Chikami S, Ipponmatsu A, Ito H, Moriwaki A, Inose R, Muraki Y, Sakaeda T.   +11 more
europepmc   +1 more source

Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL clearance and regress atherosclerosis on atorvastatin background. [PDF]

J Lipid Res
Inia JA, Zhang LH, Keijzer N, Worms N, van Nieuwkoop-van Straalen A, Ditmarsch M, de Kleer M, Jukema JW, Kastelein JJP, Szarek M, van den Hoek AM, Stokman G, Pieterman EJ, Princen HMG.   +13 more
europepmc   +1 more source

Toxic interaction between atorvastatin and clarithromycin causing myositis and rhabdomyolysis. [PDF]

Aust Prescr
Hurlbert M, Tay T, Holloway CJ, Girgis L.   +3 more
europepmc   +1 more source

Inflammatory and neurotoxic risk of atorvastatin in diabetic peripheral neuropathy: TNF-centered evidence integrating network toxicology, scRNA-Seq, and cell validation. [PDF]

Front Chem
Yang H, Chen J, Zhu P, Yuan M, Mao S, He Y, Wang X, Wang J, Wang X, Wang X.   +9 more
europepmc   +1 more source